Perceptive Advisors’s TherapeuticsMD TXMD Stock Holding History

Perceptive Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-55,000	Closed	-$3.69M	–	162
2021 Q1	$3.69M	Buy	+55,000	New	+$4.31M	0.05%	118
2020 Q2	–	Sell	-21,922	Closed	-$1.17M	–	141
2020 Q1	$1.17M	Hold	21,922	–	–	0.03%	94
2019 Q4	$2.65M	Buy	+21,922	New	+$3.15M	0.05%	86
2019 Q1	–	Sell	-30,000	Closed	-$5.71M	–	121
2018 Q4	$5.71M	Hold	30,000	–	–	0.22%	63
2018 Q3	$9.84M	Buy	+30,000	New	+$9.19M	0.26%	58
2017 Q2	–	Sell	-22	Closed	-$8K	–	155
2017 Q1	$8K	Sell	22 -5,978	-100%	-$1.85M	﹤0.01%	152
2016 Q4	$1.73M	Buy	+6,000	New	+$1.86M	0.12%	85
2014 Q2	–	Sell	-140	Closed	-$44K	–	142
2014 Q1	$44K	Buy	+140	New	+$44.6K	﹤0.01%	125

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's TXMD Position: Q2 2021 in Review

Perceptive Advisors sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 55,000 shares — an estimated $3.69M sold.

Perceptive Advisors first reported a position in TXMD in Q1 2014 and held it in 8 quarters. The position peaked at $9.84M in Q3 2018. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Perceptive Advisors reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Perceptive Advisors sold 55,000 TherapeuticsMD shares in Q2 2021, an estimated $3.69M.
Perceptive Advisors first reported a position in TherapeuticsMD in Q1 2014 and held it in 8 quarters.
Perceptive Advisors's TherapeuticsMD position peaked at $9.84M in Q3 2018.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.